ResMed Appoints Former Exact Sciences CFO Aaron Bloomer as New Finance Chief

ResMed’s finance leadership changes hands after a 27‑year tenure. Chairman and CEO Mick Farrell praised Sandercock’s two‑decade stewardship of the company’s balance sheet, noting his advisory role will continue through the end of 2027. In a seamless hand‑off, Aaron Bloomer steps in as chief financial officer on the same day Sandercock retires.

Bloomer arrives with a robust global finance pedigree. He most recently served as CFO of Exact Sciences, the cancer‑diagnostics firm now under Abbott’s umbrella, and previously held senior finance positions at Baxter International and 3M—including senior vice‑president of FP&A, regional CFO for China, and global divisional CFO for Japan. His 17‑plus years of cross‑border experience dovetails with ResMed’s push to expand its digital health platform worldwide and meet the targets outlined in its 2030 strategy.

The filing disclosed no details on Bloomer’s compensation package, sign‑on bonus, or equity awards, and ResMed did not announce any interim CFO arrangements beyond Sandercock’s advisory role.

Investors gave the news a modest nod; ResMed shares were trading at $213.74, up 0.85% on the day, while the broader market rose 1.08%. The stock remains near the bottom of its 52‑week range (4% above the low) and carries a low RSI of 29, suggesting limited upside pressure but also room for a catalyst if the new CFO can accelerate the company’s growth trajectory.

Analysts see Bloomer’s international finance background as a fit for ResMed’s expanding footprint in emerging markets and its ongoing investment in connected‑care technologies. The leadership change, while routine, underscores the company’s focus on financial discipline as it scales its subscription‑based sleep‑therapy solutions.

The transition marks the end of an era for a CFO who helped steer ResMed through pandemic‑driven demand spikes, and the beginning of a new chapter aimed at sustaining that momentum under Bloomer’s stewardship.